Hypermarcas (OTCMKTS:HYPMY) Shares Cross Below Fifty Day Moving Average - What's Next?

Key Points

• Hypermarcas shares fell below their 50-day moving average of $4.42, trading as low as $4.39, marking a notable shift in stock performance.
• Analysts have upgraded Hypermarcas to a "strong-buy" rating, reflecting increased investor confidence despite the recent stock fluctuation.
• The company's recent earnings report indicated a net margin of 11.28% and earnings per share of $0.12, contributing to a solid market capitalization of $2.79 billion.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $4.42 and traded as low as $4.39. Hypermarcas shares last traded at $4.40, with a volume of 1,819 shares trading hands.

Wall Street Analyst Weigh In

Separately, Scotiabank upgraded shares of Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Strong Buy".

Hypermarcas Price Performance

The stock's 50 day moving average price is $4.42 and its two-hundred day moving average price is $4.22. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.26 and a quick ratio of 0.80. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of 20.95 and a beta of 0.86.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.